Diagnostic Dilemmas in Hepatitis C Virus Infection for Hemodialysis Patients

Radka T. Komitova 1 , 2 , Maria V. Atanasova 3 , Toska A. Pavlova 4 , Monica Sh. Nyagolov 5  and Aneta V. Ivanova 5
  • 1 Department of Infectious Diseases, Parasitology and Tropical Medicine, Faculty of Medicine, Medical University of Plovdiv, 15A Vassil Aprilov Blvd., 4002 Plovdiv, Bulgaria Bulgaria
  • 2 Clinic of Infectious Diseases, St George University Hospital, Plovdiv, Bulgaria
  • 3 Department of Microbiology and Immunology, Faculty of Pharmacy, Medical University of Plovdiv, Plovdiv, Bulgaria
  • 4 Hemodialysis Unit, St George University Hospital, Plovdiv, Bulgaria
  • 5 Clinic of Gastroenterology, Laboratory of Porphyrias and Molecular Diagnostics of Liver Diseases, St Ivan Rilski University Hospital, Sofia, Bulgaria


Background: Hepatitis C virus (HCV) is a leading cause of chronic hepatitis in dialysis patients. The diagnosis of HCV infection in these patients is predominantly based on laboratory tests because of the specificity of the clinical course of the disease.

Aim: The present prospective study aimed at determining very accurately the prevalence rate of HCV infection in patients on dialysis by simultaneously testing them for anti-HCV and for HCV RNA levels.

Materials and methods: For the present cross-sectional longitudinal study we recruited and followed up 93 patients from St George University Hospital Hemodialysis Unit between July 2013 and December 2014. All patients were tested for anti-HCV and HCV RNA. The anti-HCV negative patients were tested for anti-HCV and HCV RNA at least twice at intervals of 6 months or more (up to 12 months). Anti-HCV antibodies were identified using a third generation ELISA assay. Commercial kits for real-time polymerase chain reaction (RT-PCR) were used to detect HCV RNA in the plasma and mononuclear cells. Aminotransferase and gammaglutamyl transpeptidase levels were studied to find if liver inflammation was present.

Results: The total seroprevalence in 68 patients was 20.6% (14). Of these, 10 patients were viremic (HCV RNA+/anti-HCV+), and 4 patients (5.9%) had discordant results (anti-HCV+/HCV RNA-). Acute hepatitis was detected in one patient. Duration of dialysis in HCV viremic patients was longer than that in aviremic patients (p=0.005).

Conclusions: The present study suggests that HCV infection in dialysis patients can be diagnosed more accurately if these patients are tested using two diagnostic methods - a serological test and a biomolecular assay. Further studies with larger sample size may prove the feasibility of such approach for all dialysis patients in this country.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Izopet J, Sandres-Sauné K, Kamar N, et al. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol 2005;77(1):70-6.

  • 2. Hinrichsen H, Leimenstoll G, Stegen G, et al. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002;51(3):429-33.

  • 3. Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European Multicentre Study. Nephrol Dial Transplant 2004;19(4):904-9.

  • 4. Kapoor M, el-Rashaid K, al-Mufti S, et al. Is dialysis environment more important than blood transfusion in transmission of hepatitis C virus during haemodialysis? [letter]. Vox Sang 1993;65:331.

  • 5. Rampino T, Arbustini E, Gregorini M, et al. Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor. Kidney Int 1999;56(6):2286-91.

  • 6. Fabrizi F, Lunghi G, Finazzi S, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 2001;38(5):1009-15.

  • 7. Urbánek P. Viral hepatitis infections in chronic kidney disease patients and renal transplant recipients. Kidney Blood Press Res 2012;35(6):454-67.

  • 8. Schneeberger PM, Keur I, van der Vliet W, et al. Hepatitis C infection in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol 1998:36:1711-5.

  • 9. Bukh J, Wantzin P, Krogsgaard K, et al. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a signifi cant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group. J Infect Dis 1993;168(6):13438.

  • 10. KDIGO. Kdigo Practical Guidelines for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008;73:S1-99.

  • 11. Cruzado JM, Casanovas-Taltavull T, Torras J, et al. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003;3(3):357-60.

  • 12. Gursoy M, Köksal R, et al. Impact of HCV infection on development of post-transplantation diabetes mellitus in renal allograft recipients. Transplant Proc 2000;32(3):561-2.

  • 13. Castillo I, Pardo M, Bartolomé J, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004;189(1):7-14.

  • 14. Barril G, Castillo I, Carreño V. Evidence of occult hepatitis C virus infection in hemodialysis patients. Am J Am Soc Nephrol 2008;19:2288-92.

  • 15. Todorov V, Boneva R, Ilieva P, et al. High prevalence of hepatitis C virus infection in one dialysis center in Bulgaria. Nephron 1998;79:222-3.

  • 16. Vladimirova N. [Epidemic outbreak of Hepatitis B and C in the center of hemodialysis.] Nosocomial infections 2009;6:78-95. [Bulgarian]

  • 17. Vazelov Е, Мushekov V. Sero-epidemiology of viral hepatitis in haemodialysis and control measures. VHPB-country meeting on “Burden and prevention of viral hepatitis in Bulgaria”: Sofi a, 24-25 March 2011.

  • 18. Vazelov E, Georgieva I, Lubih M, et al. Reduction of the incidence of HBV and HCV infection in patients treated in the Dialysis Clinic at Alexandrovska University Hospital. Nephrologia, dializa y transplantacia 2012;4:18. [Bulgarian]

  • 19. Atanasova MV, Haydouchka IA, Zlatev SP, et al. Prevalence of antibodies against hepatitis C virus and hepatitis B coinfection in healthy population in Bulgaria. A seroepidemiological study. Minerva Gastroenterol Dietol 2004;50(1):89-96.

  • 20. Espinosa M, Martin-Malo A, Alvarez de Lara MA, et al. High ALT levels predict viremia in anti-HCVpositive HD patients if a modifi ed normal range of ALT is applied. Clin Nephrol 2000;54(2):151-6.

  • 21. Guh JY, Lai YH, Yang CY, et al. Impact of decreased serum transaminase level on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995;69:459-65.

  • 22. Di Lallo D, Miceli M, Petrosillo N, et al. Risk factor of hepatitis C virus infection in patients on hemodialysis: multivariate analysis bases on a dialysis register in central Italy. Eur J Epidemiol 1999; 15:11-4.

  • 23. Periera BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Intern 1997;51:981-99.

  • 24. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36 (5 Suppl 1):S21-29.

  • 25. Takashi A, Kazuhiko H, Michio I, et al. 2011 Japanese society for dialysis therapy guidelines for the treatment of hepatitis C virus infection in dialysis patients. Ther Apher Dial 2012;16:289-310.

  • 26. Baid-Agrawal S, Schnidler R, Reinke P, et al. Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. J Hepatol 2014;60:928-33.

  • 27. Lefrere J, Guiramand S, Lefrere F, et al. Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis 1997;175:316-22.

  • 28. Pham T, MacParland S, Mulrooney P, et al. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2005;78:5867-74.

  • 29. Zachary P, Ullmann M, Djeddi S, et al. Evaluation of three commercially available hepatitis C virus antibody detection assays under the conditions of a clinical virology laboratory. J Clin Virol 2005;34:207-10.

  • 30. Vermeersch P, Rants M, Lagrou K. Validation strategy for HCV antibody testing with two enzyme immunoassays in a routine clinical laboratory. J Clin Virol 2008;42:394-8.

  • 31. Testing for HCV Infection: an update of guidance for clinicians and laboratorians. Morbidity and Mortality Weekly Report 2013;62:362-5.


Journal + Issues